Incidences of new hepatitis B infection and anti-hepatitis B core-negative occult hepatitis B infection among Japanese blood donors in relation to anti-hepatitis B surface antigen levels.
Humans
Blood Donors
/ statistics & numerical data
Incidence
Hepatitis B
/ epidemiology
Hepatitis B Surface Antigens
/ blood
Male
Hepatitis B Antibodies
/ blood
Female
Adult
DNA, Viral
/ blood
Japan
/ epidemiology
Middle Aged
Hepatitis B Core Antigens
/ blood
Young Adult
Hepatitis B virus
/ immunology
East Asian People
anti‐HBc
anti‐HBs
conversion
occult infection
secondary response
vaccination
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
Jul 2024
Jul 2024
Historique:
revised:
05
07
2024
received:
08
04
2024
accepted:
15
07
2024
medline:
23
7
2024
pubmed:
23
7
2024
entrez:
23
7
2024
Statut:
ppublish
Résumé
A transfusion-transmitted hepatitis B virus (HBV) infection caused by blood only positive for anti-hepatitis B surface antigen (anti-HBs) was reported. Occult HBV infection (OBI) with sole anti-HBs among blood donors is an issue. The incidence of HBV infection among repeat blood donors was investigated with a detailed HBV infection phase, focusing on the influence of anti-HBs level. This study followed 3 435 653 donors for HBV DNA conversion over 4 years and 9 months. Infection phase was determined based on marker changes over DNA conversion. This study identified 115 hepatitis B surface antigen (HBsAg) conversions, 72 DNA-only conversions, and 15 DNA plus anti-hepatitis B core (anti-HBc) conversions among donors all negative for HBV DNA, HBsAg, and anti-HBc. Total incidence was 2.38/100 000 person-years (PY). None of these 202 new HBV infections arose in the group with anti-HBs titer ≥ 10 mIU/mL. In total, 30 anti-HBc-negative OBIs were identified (incidence; 0.35/100 000 PY); 7 showed typical secondary anti-HBs response, and 23 showed stable anti-HBc and anti-HBs levels at DNA conversion. The HBV infection-protective ability of anti-HBs ≥ 10 mIU/mL was reinforced. In addition to new infections, the blood donor population includes anti-HBc-positive- and negative OBI with immune reactions or abortive HBV infection.
Substances chimiques
Hepatitis B Surface Antigens
0
Hepatitis B Antibodies
0
DNA, Viral
0
Hepatitis B Core Antigens
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29823Subventions
Organisme : Ministry of Health, Labour and Welfare, Japan
ID : 22HC1001
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
WHO Fact Sheet. Hepatitis B. Accessed December 2023. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
Tanaka J, Kumagai J, Katayama K, et al. Sex‐ and age‐specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first‐time blood donors during 1995‐2000. Intervirology. 2004;47(1):32‐40.
Tanaka J, Koyama T, Mizui M, et al. Total numbers of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age‐ and area‐specific prevalence on the national scale. Intervirology. 2011;54(4):185‐195.
Tanaka J, Akita T, Ohisa M, et al. Trends in the total numbers of HBV and HCV carriers in Japan from 2000 to 2011. J Viral Hepat. 2018;25(4):363‐372.
Tanaka J, Kurisu A, Ohara M, et al. Burden of chronic hepatitis B and C infections in 2015 and future trends in Japan: a simulation study. Lancet Reg Health West Pac. 2022;22:100428.
Candotti D, Allain JP. Transfusion‐transmitted hepatitis B virus infection. J Hepatol. 2009;51(4):798‐809.
Lelie N, Busch M, Kleinman S. Residual risk of transfusion‐transmitted hepatitis B virus (TT‐HBV) infection by NAT‐screened blood components: a review of observed versus modeled infectivity from donors with window period and occult HBV infections. Transfusion. 2021;61(11):3190‐3201.
Tanaka A, Yamagishi N, Hasegawa T, et al. Marked reduction in the incidence of transfusion‐transmitted hepatitis B virus infection after the introduction of antibody to hepatitis B core antigen and individual donation nucleic acid amplification screening in Japan. Transfusion. 2023;63(11):2083‐2097.
Satake M, Yamagishi N, Tanaka A, et al. Transfusion‐transmitted HBV infection with isolated anti‐HBs‐positive blood. Transfusion. 2023;63(6):1250‐1254.
FitzSimons D, Hendrickx G, Vorsters A, Van Damme P. Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? Vaccine. 2013;31(4):584‐590.
Katz L, Strong DM, Tegtmeier G, Stramer S. Performance of an algorithm for the reentry of volunteer blood donors deferred due to false‐positive test results for antibody to hepatitis B core antigen. Transfusion. 2008;48(11):2315‐2322.
Schmidt M, Nübling CM, Scheiblauer H, et al. Anti‐HBc screening of blood donors: a comparison of nine anti‐HBc tests. Vox Sang. 2006;91(3):237‐243.
Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high‐risk population in the United States. N Engl J Med. 1980;303(15):833‐841.
Francis DP. The prevention of hepatitis B with vaccine. Report of the centers for disease control multi‐center efficacy trial among homosexual men. Ann Intern Med. 1982;97(3):362‐366.
Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep. 2005;54(RR‐16):1‐31.
Pei SN, Liu YF, Kuo CY, et al. Role of quantitative hepatitis B surface antibodies in preventing hepatitis B virus‐related hepatitis in patients treated with rituximab. Leuk Lymphoma. 2021;62(12):2899‐2906.
Cho Y, Yu SJ, Cho EJ, et al. High titers of anti‐HBs prevent rituximab‐related viral reactivation in resolved hepatitis B patient with non‐Hodgkin's lymphoma. J Med Virol. 2016;88:1010‐1017.
Weber B. Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact. J Clin Virol. 2005;32(2):102‐112.
Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol. 2007;46(1):160‐170.
Shinkai N, Kusumoto S, Murakami S, et al. Novel monitoring of hepatitis B reactivation based on ultra‐high sensitive hepatitis B surface antigen assay. Liver Int. 2017;37(8):1138‐1147.
Matsumoto A, Imaizumi M, Tanaka Y, et al. Novel and highly sensitive immunoassay for total hepatitis B surface antigen, including that complexed with hepatitis B surface antibody. J Gastroenterol. 2017;52(3):376‐384.
Tang X, Allain JP, Wang H, et al. Incidence of hepatitis B virus infection in young Chinese blood donors born after mandatory implementation of neonatal hepatitis B vaccination nationwide. J Viral Hepat. 2018;25(9):1008‐1016.
Poovorawan Y, Chongsrisawat V, Theamboonlers A, Bock HL, Leyssen M, Jacquet JM. Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand. Vaccine. 2010;28(3):730‐736.
Zanetti AR, Mariano A, Romanò L, et al. Long‐term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet. 2005;366(9494):1379‐1384.
Chen Y, Lv H, Gu H, et al. The effects of different dosage levels of hepatitis B vaccine as booster on anti‐HBs‐negative children 5‐15 y after primary immunization; China, 2009‐2010. Hum Vaccin Immunother. 2014;10:498‐504.
Leuridan E, Van Damme P. Hepatitis B and the need for a booster dose. Clin Infect Dis. 2011;53:68‐75.
Poorolajal J, Hooshmand E. Booster dose vaccination for preventing hepatitis B. Cochrane Database Syst Rev. 2016;2016(6):CD008256.
Lelie N, Bruhn R, Busch M, et al. Detection of different categories of hepatitis B virus (HBV) infection in a multi‐regional study comparing the clinical sensitivity of hepatitis B surface antigen and HBV‐DNA testing. Transfusion. 2017;57(1):24‐35.
Simons BC, Spradling PR, Bruden DJT, et al. A longitudinal hepatitis B vaccine cohort demonstrates long‐lasting hepatitis B virus (HBV) cellular immunity despite loss of antibody against HBV surface antigen. J Infect Dis. 2016;214(2):273‐280.
Jarrosson L, Kolopp‐Sarda MN, Aguilar P, et al. Most humoral non‐responders to hepatitis B vaccines develop HBV‐specific cellular immune responses. Vaccine. 2004;22(27‐28):3789‐3796.
Bauer T, Jilg W. Hepatitis B surface antigen‐specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine. 2006;24(5):572‐577.
Steiner M, Ramakrishnan G, Gartner B, Van Der Meeren O, Jacquet JM, Schuster V. Lasting immune memory against hepatitis B in children after primary immunization with 4 doses of DTPa‐HBV‐IPV/Hib in the first and 2nd year of life. BMC Infect Dis. 2010;10:9.
Deng X, Guo X, Gu H, et al. Anti‐HBc‐nonreactive occult hepatitis B infections with HBV genotypes B and C in vaccinated immunocompetent adults. J Viral Hepat. 2022;29(11):958‐967.
Keating SM, Heitman JD, Wu S, et al. Cytokine and chemokine responses in the acute phase of hepatitis B virus replication in naive and previously vaccinated blood and plasma donors. J Infect Dis. 2014;209(6):845‐854.
Zheng X, Ye X, Du P, et al. High prevalence of anti‐hepatitis B core antigen in hepatitis B virus‐vaccinated Chinese blood donors suggests insufficient protection but little threat to the blood supply. Transfusion. 2015;55(4):890‐897.
Su FH, Bai CH, Chu FY, Lin YS, Su CT, Yeh CC. Significance and anamnestic response in isolated hepatitis B core antibody‐positive individuals 18 years after neonatal hepatitis B virus vaccination in Taiwan. Vaccine. 2012;30(27):4034‐4039.
Bulkow LR, Wainwright RB, Bulkow LR, Wainwright RB, McMahon BJ, Parkinson AJ. Increases in levels of antibody to hepatitis B surface antigen in an immunized population. Clin Infect Dis. 1998;26(4):933‐937.
Gessoni G, Beggio S, Barin P, et al. Significance of anti‐HBc only in blood donors: a serological and virological study after hepatitis B vaccination. Blood Transfus. 2014;12(suppl 1):s63‐s68.
Inaba S, Ito A, Miyata Y, et al. Individual nucleic amplification technology does not prevent all hepatitis B virus transmission by blood transfusion. Transfusion. 2006;46(11):2028‐2029.
Candotti D, Lin CK, Belkhiri D, et al. Occult hepatitis B infection in blood donors from South East Asia: molecular characterisation and potential mechanisms of occurrence. Gut. 2012;61(12):1744‐1753.
Wu D, Wang X, Feng F, et al. Characteristic of HBV nucleic acid amplification testing yields from blood donors in China. BMC Infect Dis. 2021;21(1):714.